Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Inventory, net — Total on balance sheet by Quarter
Inventory, net — Total on balance sheet ($M) ($M)
Moderna Inventory, net — Total on balance sheet: $280M in Q2 2026, up 16.7% from a year earlier.
Latest, Q2 2026
280
Period ended Jun 30, 2026
Change on a year earlier
+16.7%
240 in Q2 2025
History
24 quarters
Since Q4 2019
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 6 (Inventory).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Inventory, net — Total on balance sheet ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 280 | +16.7% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 146 | +14.1% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 153 | +30.8% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 332 | -19.4% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 240 | -39.8% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 128 | -56.6% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 117 | -42.1% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 412 | -15.4% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 399 | -44.2% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 295 | -59.7% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 202 | -78.7% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 487 | -76.6% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 715 | -62.8% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 732 | -62.3% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 949 | -34.1% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,077 | +115.2% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,921 | +198.8% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,942 | +293.1% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,441 | +2,966.0% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 965 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 643 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 494 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 47 | – | Form 10-K (filed 2022-02-25) ↗ |
| Q4 2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2021-02-26) ↗ |
Breakdown
What makes up inventory, net — Total on balance sheet
- Raw materials inventory ($M)117 · Q2 2026
- Work in process (drug substance & bulk formulated mRNA) inventory ($M)97 · Q2 2026
- Finished goods (filled & packaged vaccine doses) inventory ($M)66 · Q2 2026
- Gross inventory (including zero-cost raw materials awaiting destruction) ($M)361 · Q2 2026
- Prepaid manufacturing materials & CMO advances, current ($M)70 · Q2 2026
- Accounts payable — Raw materials & manufacturing suppliers ($M)44 · Q2 2026
Cite this data
StockData. (2026). Moderna Inventory, net — Total on balance sheet ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/inv-net-total
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.